Featured Stories
State Department IG: Special Inspector General for Operation Atlantic Resolve - FY 2027 Joint Strategic Oversight Plan
WASHINGTON, Oct. 28 (TNSLrpt) -- The State Department Inspector General issued the following audit reportentitled "Special Inspector General for Operation Atlantic Resolve - FY 2027 Joint Strategic Oversight Plan."
Here are excerpts:
* * *
We are pleased to submit our annual joint strategic oversight plan describing independent oversight activities for Operation Atlantic Resolve (OAR) and the U.S. Government's response to Russia's full-scale invasion of Ukraine. This plan fulfills the individual and collective independent oversight responsibilities of the Department of War (DoW), Department
... Show Full Article
WASHINGTON, Oct. 28 (TNSLrpt) -- The State Department Inspector General issued the following audit reportentitled "Special Inspector General for Operation Atlantic Resolve - FY 2027 Joint Strategic Oversight Plan."
Here are excerpts:
* * *
We are pleased to submit our annual joint strategic oversight plan describing independent oversight activities for Operation Atlantic Resolve (OAR) and the U.S. Government's response to Russia's full-scale invasion of Ukraine. This plan fulfills the individual and collective independent oversight responsibilities of the Department of War (DoW), Departmentof State (State), and U.S. Agency for International Development (USAID) Inspectors General (IG) under the IG Act of 1978, as amended, and the National Defense Authorization Act (NDAA) of 2024. We continuously monitor changing conditions and periodically review our ongoing and planned oversight projects.
This enables us to adjust our coordinated oversight to ensure that it is always relevant and timely. This FY 2027 Joint Strategic Oversight Plan is effective as of October 1, 2026. Further details about completed, ongoing, and planned work by the DoW, State, and USAID OIGs and partner agencies related to OAR, including U.S. Government assistance to Ukraine can be found at UkraineOversight.gov.
* * *
View full audit report at: https://www.stateoig.gov/uploads/report/report_pdf_file/fy-2027-jsop_oar_final_261015_508.pdf
State Department IG: Inspection of Embassy Tbilisi, Georgia
WASHINGTON, Oct. 28 (TNSLrpt) -- The State Department Inspector General issued the following audit report (No. ISP-I-27-07) entitled "Inspection of Embassy Tbilisi, Georgia."
Here are excerpts:
* * *
What OIG Inspected
OIG inspected Embassy Tbilisi's advancement of foreign policy goals and objectives, policy and program implementation, consular operations, resource management, and information management.
What OIG Found
* Embassy Tbilisi generally advanced U.S. foreign policy goals in accordance with U.S. Department of State standards.
* Due to the Department's foreign assistance pause,
... Show Full Article
WASHINGTON, Oct. 28 (TNSLrpt) -- The State Department Inspector General issued the following audit report (No. ISP-I-27-07) entitled "Inspection of Embassy Tbilisi, Georgia."
Here are excerpts:
* * *
What OIG Inspected
OIG inspected Embassy Tbilisi's advancement of foreign policy goals and objectives, policy and program implementation, consular operations, resource management, and information management.
What OIG Found
* Embassy Tbilisi generally advanced U.S. foreign policy goals in accordance with U.S. Department of State standards.
* Due to the Department's foreign assistance pause,the Embassy's foreign assistance funding dropped from an estimated $37.6 million in FY 2025 to $1.4 million in FY 2026.
* Embassy Tbilisi's Political and Economic, Public Diplomacy, and Consular Sections generally complied with Department standards.
* In the resource management area, the Embassy had deficiencies in its life safety and motor pool programs.
* The Embassy had deficiencies in its information management operations related to information systems security and telephone operations.
What OIG Recommends
OIG made 6 recommendations to Embassy Tbilisi. In its comments on the draft report, Embassy Tbilisi concurred with 5 recommendations and partially concurred with 1 recommendation. OIG considers all 6 recommendations resolved. The Embassy's formal response is reprinted in its entirety in Appendix B.
* * *
View full audit report at: https://www.stateoig.gov/uploads/report/report_pdf_file/isp-i-27-07.pdf
SBA Asks Public to Report Suspected Pandemic-Era Fraud Through DOJ Whistleblower Portal
WASHINGTON, Oct. 28 -- The Small Business Administration issued the following news release:
* * *
SBA Asks Public to Report Suspected Pandemic-Era Fraud Through DOJ Whistleblower Portal
Whistleblower Program Offers Incentives for Reporting PPP and COVID EIDL Fraud
October 27, 2026
WASHINGTON -- Following President Donald J. Trump's announcement establishing the Fraud Whistleblower Incentive Program (WHIP), the U.S. Small Business Administration (SBA) today called on members of the public, federal employees, lenders, and small business owners to report suspected SBA loan and grant fraud through
... Show Full Article
WASHINGTON, Oct. 28 -- The Small Business Administration issued the following news release:
* * *
SBA Asks Public to Report Suspected Pandemic-Era Fraud Through DOJ Whistleblower Portal
Whistleblower Program Offers Incentives for Reporting PPP and COVID EIDL Fraud
October 27, 2026
WASHINGTON -- Following President Donald J. Trump's announcement establishing the Fraud Whistleblower Incentive Program (WHIP), the U.S. Small Business Administration (SBA) today called on members of the public, federal employees, lenders, and small business owners to report suspected SBA loan and grant fraud throughthe new centralized federal portal at america.gov/fraud.
"Since Day One, the Trump SBA has been laser-focused on addressing the $200 billion in potential Paycheck Protection Program and COVID-EIDL fraud that was identified - but went unaddressed - during the Biden Administration," said SBA Administrator Kelly Loeffler. "With the support of the White House Fraud Task Force, we have exposed billions in suspected fraud, sent billions more to Treasury for collections, and delivered real accountability to criminal fraudsters. Now, through President Trump's Fraud Whistleblower Incentive Program, we are offering Americans the platform and the financial incentives to help expose bad actors and deliver justice on behalf of honest business owners and taxpayers. The SBA encourages members of the public to report suspected fraud--including fraud tied to pandemic loan programs--at america.gov/fraud."
The new program comes as the SBA continues its sweeping review of pandemic-era financial assistance, including the Paycheck Protection Program (PPP) and COVID Economic Injury Disaster Loan (COVID EIDL) Program. During the Biden Administration, the SBA Office of Inspector General estimated that more than $200 billion of the approximately $1.2 trillion disbursed through pandemic relief programs went to potentially fraudulent recipients. In close collaboration with the White House Task Force to Eliminate Fraud, the Trump SBA has aggressively scrutinized that legacy portfolio to uncover illicit activity and pursue enforcement action.
To date, the Trump SBA has helped expose approximately $122 billion in suspected pandemic-era fraud through coordinated referrals to federal partners. An SBA referral to the Internal Revenue Service led to the identification of discrepancies associated with approximately $100 billion in PPP and COVID EIDL loans, while the agency separately referred approximately $22 billion in suspected fraudulent PPP and COVID EIDL debt to the U.S. Department of the Treasury for collection. In addition to these referrals, the SBA has announced suspensions for approximately 1 million borrowers tied to about $50 billion in suspected pandemic-era fraud, barring them from future SBA lending and federal contracting programs.
The new Fraud Whistleblower Incentive Program, administered by the U.S. Department of Justice's National Fraud Enforcement Division, incentivizes individuals with direct knowledge of federal program theft, fraud, or misuse to submit tips. Under the program, qualifying whistleblowers whose original information leads to successful federal enforcement actions or criminal charges can receive cash rewards.
The SBA is specifically urging the public, federal employees, industry insiders, and bank compliance officers to submit tips regarding potential fraud across pandemic relief programs, including PPP, COVID EIDL, the Shuttered Venue Operators Grant (SVOG) Program, and the Restaurant Revitalization Fund (RRF). Examples of potentially fraudulent or improper conduct may include:
* Submitting false, fabricated, or altered financial records, payroll reports, or tax documents to secure SBA-backed commercial financing.
* Misrepresenting business ownership, size, location, or veteran or disadvantaged status to secure federal contracting set-asides or grant awards.
* Using SBA loan proceeds, disaster loans, or grant funds for personal enrichment.
* Unlawful kickbacks, fee-splitting, or misrepresentations involving the identities of loan packagers, brokers, or borrowers.
* Continued possession or misuse of government assistance by phantom or shell entities.
The new Fraud Whistleblower Incentive Program creates a streamlined reporting portal directly through america.gov/fraud, allowing anyone to safely submit documentation, financial records, and evidence to federal investigators. Qualifying whistleblowers whose information leads to the filing of criminal charges may receive monetary awards, subject to program requirements and the DOJ's discretion. Anyone who suspects fraudulent activity in any SBA program is encouraged to visit america.gov/fraud to submit a report.
* * *
About the U.S. Small Business Administration
The U.S. Small Business Administration helps power the American dream of entrepreneurship. As the leading voice for small businesses within the federal government, the SBA empowers job creators with the resources and support they need to start, grow, and expand their businesses or recover from a declared disaster. It delivers services through an extensive network of SBA field offices and partnerships with public and private organizations. To learn more, visit www.sba.gov.
* * *
Original text here: https://legacy.sba.gov/article/2026/10/27/sba-asks-public-report-suspected-pandemic-era-fraud-through-doj-whistleblower-portal
Postal Service IG: Michigan 1 District: Delivery Operations
WASHINGTON, Oct. 28 (TNSLrpt) -- The U.S. Postal Service Inspector General issued the following audit report (No. 26-087-R27) on October 15, 2026, entitled "Michigan 1 District: Delivery Operations."
Here are excerpts:
* * *
During the week of May 5, 2026, we performed a self-initiated audit at the Detroit Processing and Distribution Center (P&DC), and three delivery units serviced by the P&DC. The delivery units included Grand Shelby Carrier Annex, Gratiot Station, and Strathmoor Station Detroit, MI.
We issued individual reports for the three delivery units and one report for the P&DC. We
... Show Full Article
WASHINGTON, Oct. 28 (TNSLrpt) -- The U.S. Postal Service Inspector General issued the following audit report (No. 26-087-R27) on October 15, 2026, entitled "Michigan 1 District: Delivery Operations."
Here are excerpts:
* * *
During the week of May 5, 2026, we performed a self-initiated audit at the Detroit Processing and Distribution Center (P&DC), and three delivery units serviced by the P&DC. The delivery units included Grand Shelby Carrier Annex, Gratiot Station, and Strathmoor Station Detroit, MI.
We issued individual reports for the three delivery units and one report for the P&DC. Wealso issued another report summarizing the results of our audits at all three delivery units with specific recommendations for management to address.
The audit team identified deficiencies in five areas we reviewed affecting mail delivery and property conditions at the three delivery units.
* * *
View the original text at: https://www.uspsoig.gov/sites/default/files/reports/2026-10/26-087-r27.pdf
FDA Center for Drug Evaluation & Research Issues Warning Letter to TSP Solutions
WASHINGTON, Oct. 28 (TNSdock) -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to TSP Solutions Pte. Ltd. from its Center for Drug Evaluation and Research:
* * *
Recipient: Mr. Min-tsek Lau, Managing Director, TSP Solutions Pte. Ltd., Block 998 Toa Payoh North, #05-05/06 Mapletree Industrial, 318993, Singapore, mintsek@tspsolutions.co
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
WARNING LETTER
Reference number: 320-27-07
To Mr. Min-tsek Lau:
This warning letter advises you of significant
... Show Full Article
WASHINGTON, Oct. 28 (TNSdock) -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to TSP Solutions Pte. Ltd. from its Center for Drug Evaluation and Research:
* * *
Recipient: Mr. Min-tsek Lau, Managing Director, TSP Solutions Pte. Ltd., Block 998 Toa Payoh North, #05-05/06 Mapletree Industrial, 318993, Singapore, mintsek@tspsolutions.co
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
WARNING LETTER
Reference number: 320-27-07
To Mr. Min-tsek Lau:
This warning letter advises you of significantviolations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.
FDA Review
Violations were identified and documented during review of your drug manufacturing facility, TSP Solutions Pte. Ltd., FDA Establishment Identifier (FEI) 3023093622. This review was conducted under FDA's statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.
Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 9, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.
This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).
Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).
Violations of the Federal Food, Drug, and Cosmetic Act
The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.
1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release; and, your firm failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).
Your firm manufactures sunscreen drug products.
Based on the records and information you provided, you did not demonstrate that you conduct adequate finished drug product testing on your drug products. Specifically, neither the certificate of analysis (COA) reports nor the batch records that you provided include an appropriate assay test for active ingredient content or impurity testing. In addition, your records do not include appropriate microbiological testing.
Full release testing, including strength and identity testing of the active ingredient, as well as appropriate microbiological testing, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to ensure that your drug products conform to appropriate specifications before release.
In response to this letter, provide:
* A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.
* An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.
* A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.
2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier's test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).
Based on the records and information you provided, you did not demonstrate that you are adequately testing the identity of incoming components used in the manufacture of your drug products. Your response also indicated that you accept your supplier's COA without verifying the test results at appropriate intervals. Verification of component quality is performed only by reviewing the COAs and material safety data sheets provided by the suppliers.
Without adequate testing and without establishing the reliability of your component suppliers' test analyses at appropriate intervals, you do not have scientific evidence that your raw materials conform to appropriate specifications before you use them in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before you use them in production to ensure adequate quality.
In response to this letter, provide:
* A comprehensive, independent review of your material system, including but not limited to:
- evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified
- an assessment of all materials to determine whether they are consistently of acceptable quality based on thorough historical review
- a review to ensure assigned expiration or retest dates are appropriate (supported by data)
- adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions
- vigilant lifecycle monitoring of all suppliers using sound quality risk management practices
- based on this thorough review, summarize a systemic CAPA that remediates the materials system to ensure ongoing lifecycle oversight of vendor performance and prevents use of unsuitable components (ingredients), containers and closures.
* The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.
* A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier's COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier's results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.
* A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.
* A summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.
3. Your firm's quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).
Based on the records and information you provided, your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:
* Adequate procedures ensuring appropriate production and process controls for drug product manufacturing and qualification of equipment used to manufacture drug products (21 CFR 211.100(a)).
* Adequate laboratory control procedures to ensure drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).
* The establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).
Your firm's quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA's guidance documents Quality Systems Approach to Pharmaceutical CGMP Regulations at https://www.fda.gov/media/71023/download.
CGMP Consultant Recommended
Based upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm's compliance status with FDA.
Your use of a consultant does not relieve your firm's obligation to comply with CGMP. Your firm's executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.
Conclusion
As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.
FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 14, 2026.
FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.
Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at TSP Solutions Pte. Ltd., at Block 998 Toa Payoh North, #05-05/06 Mapletree Industrial, Singapore 318993, Singapore, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).
Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within 15 business days of receipt of this letter. Identify your written response with FEI 3023093622 and ATTN: Bryce Hammer in the subject line of the email.
If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.
FDA posts warning letters to www.FDA.gov.
Sincerely,
/S/ Francis Godwin, Director, Office of Manufacturing Quality, Office of Compliance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Cc: Registered U.S. Agent
Mr. David Lennarz
Registrar Corp
drugs@registrarcorp.com
* * *
Original text here: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tsp-solutions-pte-ltd-735071-10222026
Education IG: Short-Term Program Eligibility Compliance: National Holistic Institute
WASHINGTON, Oct. 28 -- The U.S. Department of Education Inspector General issued the following audit report information on October 13, 2026, entitled "Short-Term Program Eligibility Compliance: National Holistic Institute":
Here are excerpts:
* * *
What We Did
Section 481(b)(2) of the Higher Education Act of 1965, as amended (HEA), requires postsecondary institutions' short-term programs to provide training that prepares a student for gainful employment, and to have verified completion and placement rates of at least 70 percent to be eligible to participate in the William D. Ford Federal Direct
... Show Full Article
WASHINGTON, Oct. 28 -- The U.S. Department of Education Inspector General issued the following audit report information on October 13, 2026, entitled "Short-Term Program Eligibility Compliance: National Holistic Institute":
Here are excerpts:
* * *
What We Did
Section 481(b)(2) of the Higher Education Act of 1965, as amended (HEA), requires postsecondary institutions' short-term programs to provide training that prepares a student for gainful employment, and to have verified completion and placement rates of at least 70 percent to be eligible to participate in the William D. Ford Federal DirectLoan (Direct Loan) program. We conducted this work, in part, given the significance of provisions in the One Big Beautiful Bill Act that expand eligibility for the Federal Pell Grant program to include short-term programs. Beginning July 1, 2026, students are able to receive Pell Grant funds to enroll in short-term programs that offer education in high skill, high wage, or in demand industry sectors or occupations. This change is expected to increase the number of short-term programs that institutions offer and the number of students enrolled in such programs.
We inspected National Holistic Institute's (NHI) compliance with short-term program requirements-- specifically, whether NHI's Advanced Neuromuscular Massage Therapy (ANMT) program met the completion and placement rate requirements for the 2023- 2024 award year.
What We Found
NHI's ANMT program did not meet all short-term program eligibility requirements in the HEA. Specifically, it did not maintain at least a 70 percent placement rate. NHI incorrectly calculated its program's placement rate for the 2023-2024 award year by including students who should have been excluded from this calculation. Because it did not meet eligibility requirements, NHI's program became ineligible for the Direct Loan program as of the 2024-2025 award year. In addition, because NHI provided an inaccurate placement rate percentage, prospective students and their parents might have made enrollment decisions based on this unreliable information.
What We Recommend
We made three recommendations to the Chief Operating Officer for Federal Student Aid (FSA) to require NHI officials to design and implement effective procedures and return all Direct Loan funds awarded to students enrolled in the short-term program after the 2023-2024 award year. In addition, we recommended that the Chief Operating Officer for FSA review the Title IV eligibility of NHI's short-term program for award years beginning on or after July 1, 2024.
* * *
Access the report at: https://oig.ed.gov/sites/default/files/reports/2026-10/FY27%20I25NY0266%2810.13.26%29v100_508_SECURED.pdf
EPA to Hold Public Meeting on Modification of Remedy at New Bedford Harbor Superfund Site on October 28, 2026
WASHINGTON, Oct. 28 -- The Environmental Protection Agency issued the following news release:
* * *
EPA to Hold Public Meeting on Modification of Remedy at New Bedford Harbor Superfund Site on October 28, 2026
*
BOSTON, MASS (Oct. 19, 2026) -- U.S. Environmental Protection Agency (EPA) is hosting a virtual public meeting on October 28, 2026, at 6:00 p.m. via Microsoft Teams to present the draft eighth Explanation of Significant Differences (ESD) proposing to modify the upper and lower harbor remedy for the New Bedford Harbor Superfund Site.
Under the ESD, EPA would remove soil in areas where
... Show Full Article
WASHINGTON, Oct. 28 -- The Environmental Protection Agency issued the following news release:
* * *
EPA to Hold Public Meeting on Modification of Remedy at New Bedford Harbor Superfund Site on October 28, 2026
*
BOSTON, MASS (Oct. 19, 2026) -- U.S. Environmental Protection Agency (EPA) is hosting a virtual public meeting on October 28, 2026, at 6:00 p.m. via Microsoft Teams to present the draft eighth Explanation of Significant Differences (ESD) proposing to modify the upper and lower harbor remedy for the New Bedford Harbor Superfund Site.
Under the ESD, EPA would remove soil in areas wherepolychlorinated biphenyl (PCB) contamination is higher than 1 part per million. The contaminated soil would be excavated to a depth of three feet and replaced with clean soil. The plan would also include land use controls for the property. These controls would allow the City of New Bedford to pursue residential development on the site, but would require a soil management plan to make sure any PCB-contaminated soil located deeper than three feet would be handled safely, if it were to be disturbed in the future.
"The City of New Bedford has been a key partner during EPA's implementation of the Superfund remedy, allowing EPA to perform remedy support work at the City's Sawyer Street property since the 1980s," said EPA Regional Administrator Mark Sanborn. "This proposed work is an important step as we near completion of the New Bedford Harbor Superfund Site cleanup."
EPA is seeking public input on the draft ESD during the 30-day public comment period starting on October 30, 2026, and ending on November 28, 2026. Beginning on October 30, 2026, the draft ESD Administrative Record can be reviewed and comments submitted via https://www.regulations.gov (Docket ID No. EPA-R01-SFUND-2026-6304). All comments are reviewed and responded to in writing by EPA prior to selecting a final alternative for the ESD, if necessary.
Meeting materials and link to join October 28th meeting at 6:00 p.m. will be posted prior to the meeting on https://www.epa.gov/new-bedford-harbor.
***
Original text here: https://www.epa.gov/newsreleases/epa-hold-public-meeting-modification-remedy-new-bedford-harbor-superfund-site-october
